Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + Tislelizumab in B-Cell Lymphoid Malignancies
NCT02795182Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jun 2016
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 8 more, sponsored by BeiGene. Primary endpoints: Maximum Tolerated Dose of Tislelizumab and Recommended Phase 2 Dose of Tislelizumab. Started Jun 2016; status: completed.
02
Drugs
tislelizumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT02795182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795182.